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Astrocyte Specific Remodeling 
of Plasmalemmal Cholesterol 
Composition by Ketamine 
Indicates a New Mechanism of 
Antidepressant Action
Eva Lasič1, Marjeta Lisjak1, Anemari Horvat1,2, Mićo Božić1, Aleksandra Šakanović3, 
Gregor Anderluh  3, Alexei Verkhratsky2,4,5,6, Nina Vardjan1,2, Jernej Jorgačevski1,2, 
Matjaž Stenovec1,2 & Robert Zorec1,2
Ketamine is an antidepressant with rapid therapeutic onset and long-lasting effect, although 
the underlying mechanism(s) remain unknown. Using FRET-based nanosensors we found that 
ketamine increases [cAMP]i in astrocytes. Membrane capacitance recordings, however, reveal 
fundamentally distinct mechanisms of effects of ketamine and [cAMP]i on vesicular secretion: a rise 
in [cAMP]i facilitated, whereas ketamine inhibited exocytosis. By directly monitoring cholesterol-
rich membrane domains with a fluorescently tagged cholesterol-specific membrane binding domain 
(D4) of toxin perfringolysin O, we demonstrated that ketamine induced cholesterol redistribution in 
the plasmalemma in astrocytes, but neither in fibroblasts nor in PC 12 cells. This novel mechanism 
posits that ketamine affects density and distribution of cholesterol in the astrocytic plasmalemma, 
consequently modulating a host of processes that may contribute to ketamine’s rapid antidepressant 
action.
Major depressive disorder (MDD) affects up to 20% of the population and is the leading cause of disability world-
wide1; therapeutic containment is frequently unsuccessful. Most current antidepressants target the monoamin-
ergic system, which reflects the research focus on monoamines in recent decades. However, this direction is not 
fully justified given the widely acknowledged discrepancy between rapid modulation of monoaminergic targets 
and long-lasting delay of therapeutically relevant responses2.
Ketamine, an anesthetic and psychotomimetic, has gained much attention due to its rapid and long-lasting 
antidepressant effects3. Ketamine is considered as a non-competitive N-methyl-d-aspartate receptor (NMDAR) 
antagonist; its antidepressant action is in agreement with the glutamatergic hypothesis of MDD4. It postulates 
that NMDAR antagonism increases the synthesis of brain-derived neurotrophic factor (BDNF)5, which results 
in an antidepressant effect. Unlike classic antidepressants, a single administration of ketamine exerts fast and 
long-lasting effects, indicating a fundamentally distinct mechanism6. Ketamine treatment has a singularly wide 
impact on nervous tissue; it increases synaptogenesis, elevates the density of dendritic spines, and boosts the 
expression of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors5,7. Furthermore, other 
NMDAR antagonists, in contrast to ketamine, do not produce antidepressant effects8,9, indicating that ketamine 
may affect targets other than NMDAR. Of note, the antidepressant effects of (R)-ketamine are more potent over 
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a longer period compared to (S)-ketamine10, indicating specific ketamine enantiomer-mediated antidepressant 
activity.
The complexity of ketamine-mediated antidepressant effects has been further highlighted by a finding that 
ketamine modulates cyclic adenosine monophosphate (cAMP) signaling in the absence of NMDAR11. Signaling 
through cAMP is reduced in patients with depression, whereas treatment with selective serotonin reuptake inhib-
itors (SSRIs) increases cAMP levels12. Thus, ketamine may act similarly to SSRIs, since it potentiates adrenergic 
receptor-mediated increases in cAMP in C6 glioma cells11.
Ketamine also modifies presynaptic exo-/endocytotic machinery by altering the protein levels of SNARE (sol-
uble NSF-attachment protein receptor) complex, as well as expression of vesicle-fusing ATPase, synaptotagmin-1, 
syntaxin-1A, synapsin-1, and syndapin-113–15. Ketamine suppresses Ca2+ transients in astrocytes16, and aberrant 
astrocytic Ca2+ homeostasis may have an impact on vesicle dynamics and astroglial secretion17. Our previous 
experiments demonstrated that ketamine modulates the interaction between the vesicle and the plasmalemma 
by stabilizing the fusion pore in a narrow configuration18. This effect is reminiscent of the action of cAMP in 
secretory pituitary cells where cAMP promotes fusion pore flickering19. Hence, ketamine may act on exocytosis 
by affecting the cAMP signaling cascade.
cAMP may regulate synaptic activity by increasing secretion of BDNF and catecholamines20; in addition 
cAMP stimulates cellular differentiation and increases regulated exocytosis in astrocytes21. In other secretory 
cells, cAMP regulates exocytosis22 by acting directly on the secretory machinery23, increasing vesicle docking effi-
ciency24 or the sensitivity of secretory proteins to Ca2+ 23, enhancing vesicle mobility25, or promoting homotypic 
intracellular vesicle-to-vesicle fusion26.
We tested the hypothesis that ketamine modifies astroglial secretion through cAMP signaling and confirmed 
that ketamine does stimulate cAMP production in astrocytes. Nonetheless, we also found that ketamine does not 
modulate exocytosis through cAMP, but via different mechanism(s). Ketamine is an amphipathic molecule capa-
ble of direct interaction with the plasmalemma27. Hence, we hypothesized that the ketamine-mediated increase 
in cAMP signaling may involve structural membrane changes, leading to the translocation of G-proteins in lipid 
rafts11. By visualizing cholesterol-rich plasmalemmal domains, we demonstrated that ketamine redistributes these 
domains in the plasmalemma of astrocytes, but not in PC12 cells and fibroblasts. This novel mechanism, capable 
of modulating multiple cellular functions, may well contribute to ketamine’s powerful antidepressant effect.
Results
Ketamine Increases [cAMP]i in Astrocytes. We monitored the effects of ketamine on the dynamics of 
[cAMP]i in astrocytes expressing the cAMP FRET nanosensor Epac1-camps28 (Fig. 1a). Application of 25 μM 
ketamine elicited a significant (>20 µM) increase in [cAMP]i that persisted throughout the recording time (900 s; 
Fig. 1b, right), with an average amplitude of the CFP/YFP (FRET) signal of 13.6 ± 5.7% (n = 9) and an initial rate 
of increase in the FRET signal indicating a rate of cAMP production, of 1.7 ± 0.8%/min (n = 9). The increase in 
the FRET signal started with a delay of 219 ± 52 s (n = 9) after onset of ketamine application. The amplitude and 
the initial rate of the FRET signal change in ketamine-stimulated cells differed from controls (13.6 ± 5.7% vs. 
−0.4 ± 0.6%; P < 0.01, n = 15) and 1.7 ± 0.8%/min vs. −0.1 ± 0.1%/min (P < 0.05, n = 15), respectively; Fig. 1). 
Ketamine thus increases astrocytic [cAMP]i.
cAMP Facilitates Full Fusion of Larger Non-synaptic-like Vesicles. Next, we examined how 
membrane-permeable cAMP-AM that increases [cAMP]i modulates vesicle dynamics in astrocytes by measur-
ing unitary fusion and fission membrane capacitance steps, the amplitude of which permits vesicle size estima-
tion29–31. The mean diameter of vesicles that transiently fused with the plasmalemma was smaller (P < 0.001) in 
cAMP-treated (187 ± 6 nm, n = 202) than in control astrocytes (233 ± 10 nm, n = 221) (Fig. 2a). The proportion 
of transiently fusing vesicles with capacitance larger than 1 fF was accordingly smaller in cAMP-treated cells (41% 
[n = 83/202] vs. 62% [n = 138/221]). Conversely, the mean diameter of vesicles undergoing full fusion was signif-
icantly larger (P < 0.01) in cAMP-treated astrocytes (419 ± 36 nm, n = 48) than in controls (285 ± 24 nm, n = 40; 
Fig. 2b). Similarly, the proportion of full fusion of vesicles with capacitance >1 fF was larger in cAMP-treated 
cells (85% [n = 41/48] vs. 70% [n = 28/40]). Consistent with studies on endocrine cells19, our results indicate that 
astroglial vesicles that exhibit transient interactions with the plasmalemma (Fig. 2a, top right) in control condi-
tions likely undergo full fusion after cAMP treatment (Fig. 2b, bottom right).
These findings were corroborated by microscopic measurements revealing that the size (surface area) and 
number of ANP-positive vesicles (Supplementary Fig. 1a, left), decreased after cAMP treatment (Supplementary 
Fig. 1a, right, and Supplementary Fig. 1b). After cAMP treatment, similar decreases were observed in vesicles 
immunopositive for VAMP2/3 (Supplementary Fig. 1c–f), and LC3-immunopositive autophagosomes32–37 
(Supplementary Fig. 1g,h). These results suggest that cAMP stimulates exocytotic secretion of large non-synaptic 
vesicles, without affecting small synaptic-like secretory vesicles.
cAMP did not affect vesicles that underwent full fission from the plasmalemma. The mean diameter and 
the relative proportion of larger endocytotic vesicles were comparable in untreated and cAMP-treated cells 
(204 ± 14 nm [n = 102] vs. 192 ± 8 nm [n = 175] and 33% [n = 34/102] vs. 42% [n = 74/175]; Fig. 2c). In contrast, 
immunolabelling of early endosomes with the antibody against early endosomal marker EEA1 and vesicle loading 
with fluorescent dextrans revealed a cAMP-mediated effect on early endosomes. EEA1-positive endosomes were 
significantly larger after cAMP treatment (Supplementary Fig. 2a–c). Similarly, significantly larger dextran-loaded 
vesicles were observed after cAMP treatment when compared to controls; after 15 min (Supplementary Fig. 2d–f) 
and 3 h incubation, respectively (Supplementary Fig. 2g–i). These results suggest that cAMP stimulates intra-
cellular fusion between early endosomes, similar to the cAMP-mediated intracellular vesicle-to-vesicle fusion 
reported in endocrine cells26.
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cAMP Favors an open fusion pore state of astroglial vesicles. In vesicles undergoing transient 
fusion/fission, the dwell time of an open or closed fusion pore can be determined (Fig. 3a); the open pore dwell 
time defines the time during which exocytotic cargo can be released from the vesicle lumen, whereas the closed 
pore dwell time defines the time of no release. Figure 3a depicts a representative recording of transient fusion 
and transient fission that can be interpreted as follows: at first, the baseline (dotted line) represents a state where 
vesicle “1” has a closed pore and vesicle “2” has an open pore. During the transient fusion, vesicle “1” opens and 
then closes its fusion pore to return to “baseline”. Later on in the recording, vesicle “2” closes its pore during 
transient fission and then reopens it to return to the “baseline”. The dwell times measured in this study ranged 
from 0.016 to 12.3 s. The open pore dwell time of 0.404 ± 0.087 s (n = 95) in controls was (P < 0.001) shorter than 
in cAMP-treated cells (1.03 ± 0.167 s, n = 106; Fig. 3b); this change may facilitate vesicle cargo discharge. The 
closed pore dwell time of 0.673 ± 0.161 s (n = 126) in controls was longer (P < 0.05) than in cAMP-treated cells 
(0.341 ± 0.079 s, n = 96; Fig. 3c). cAMP prolongs the open fusion pore configuration and shortens the closed 
fission pore configuration, which most likely facilitates vesicle cargo discharge. Although prolonged fusion dwell 
Figure 1. Ketamine increases [cAMP]i in cultured rat astrocytes. (a) Schematic representation of the FRET-
based Epac1-camps nanosensor activity (top) and pseudocolour FRET signal images of an astrocyte expressing 
the FRET-based nanosensor Epac1-camps before (−41 s) and after (+600 s) exposure to 25 µM ketamine 
(bottom) and the corresponding normalized time course of the Epac1-camps FRET signal (YFP/CFP). The 
pseudocolour scale depicts the YFP/CFP ratio values. Scale bar, 20 µm. (b) Time courses (left panel) and mean 
time course (±SE; right panel) of the Epac1-camps FRET signal in cells stimulated with ketamine (n = 9) at 
t = 0 s (black arrows). Data are expressed as the inverse FRET signal (CFP/YFP). The increase in the FRET signal 
after the addition of ketamine reflects an increase in [cAMP]i. The initial rate of change in [cAMP]i (red line; 
right panel) was determined by fitting the regression line to the initial FRET signal increase (k = 2.2 ± 0.6%/
min). Ordinate on the right shows the values of [cAMP]i estimated from equation: [cAMP]i = EC50 × ((R − 
Rmin)/(Rmax − R))1/n 73. (c) Mean amplitude (±SE; ΔFRET; left panel) and initial rate of the FRET signal change 
(ΔFRET/Δtime; right panel) in controls (white bars) and in cells stimulated with ketamine (black bars). 
Changes in the FRET signal are expressed as percentages of the initial values. Numbers above the error bars 
depict the number of cells analyzed. Mann-Whitney U test: *P < 0.05, **P < 0.01.
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times could be related to an increase in full fusion events, our analysis indicated that cAMP had no effect on the 
frequency of full (or transient) fusions.
In contrast to ketamine18, cAMP increases vesicle fusion pore conductance that can be measured when dis-
crete events in the imaginary admittance signal (Im) are projected to the real admittance signal (Re)38. The pro-
jection is the result of the formation of a narrow fusion pore that acts as an additional resistive element in the 
equivalent electrical circuit. Due to the detection limit39, the electrophysiological method enabled us to record 
fusion pores with conductance between 16.6 and 4201 pS, i.e. fusion pores with estimated diameter between 0.5 
and 8.7 nm (Fig. 4a,b). Fusion pores with diameter >8.7 nm did not cause projections to Re and were thus unde-
tectable. In controls, the proportion of transient projected exocytotic events was 84% (n = 185/221), whereas 
in cAMP-treated cells, this proportion was reduced to 66% (n = 133/202) (Fig. 4c). Thus, the proportion of 
transient fusion pores with diameter >8.7 nm increased from 16% in controls to 34% in cAMP-treated cells. 
Correspondingly, the relative conductance of fusion pores (normalized to vesicle capacitance) was significantly 
Figure 2. cAMP causes larger non-synaptic-like vesicles to transit to full fusion in astrocytes. (a–c) 
Electrophysiological recordings of the imaginary (Im) and real (Re) parts of the admittance signals (bottom) and 
the corresponding diagrams of vesicle interactions with the plasmalemma (top). * denote calibration pulses. 
(a) The diameter of vesicles undergoing transient fusion/fission with the plasmalemma is smaller in cAMP-
treated cells (middle). Frequency distributions of Cv (right) reveal a greater proportion (%) of larger vesicles in 
untreated than in cAMP-treated cells. (b) The diameter of exocytotic vesicles undergoing full fusion is larger in 
cAMP-treated cells (middle). Frequency distributions (right) reveal a greater proportion (%) of larger vesicles 
undergoing full fusion in cAMP-treated cells. (c) The diameter of endocytotic vesicles undergoing full fission in 
untreated cells and in cAMP-treated cells is similar (middle), as are the frequency distributions (right). Values 
displayed in the graphs (%) denote the proportion of vesicles larger than 1 fF (vertical dotted line). Numbers in 
the bars denote vesicle number. **P < 0.01, ***P < 0.001 (Mann-Whitney U test).
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larger (P < 0.01) in cAMP-treated cells (81.8 ± 3.7 pS/fF, n = 290) than in controls (72.6 ± 3.4 pS/fF, n = 285; 
Fig. 4d). These results demonstrate that cAMP widens the fusion pore, opposite to the action of ketamine18, which 
indicates that ketamine-induced vesicle fusion pore modulation is not mediated by ketamine-induced increases 
in [cAMP]i (Fig. 1).
Ketamine Increases the Density of Cholesterol Domains in the Astroglial Plasmalemma. As 
the increase in [cAMP]i did not mimic the effects of ketamine on vesicle fusion/fission described previously18, 
we considered a possible direct interaction between ketamine, an amphipathic molecule, and the plasmalemma. 
We monitored cholesterol-rich domains in the plasmalemma of different cell types with a fluorescently tagged 
cholesterol-specific membrane-binding domain of perfringolysin O (D4)40,41. Confocal microscopy revealed 
a punctate D4 fluorescence pattern, representing cholesterol-rich domains to which CT-B-labelled ganglio-
side monosialic acid (GM1), a marker of sphingolipid- and cholesterol-rich lipid rafts, co-localized substan-
tially (Fig. 5a); 45.6 ± 2.4% (n = 47) as determined by quantitative fluorescence co-localization analysis (CT-B 
vs. mCherry-D4). Super-resolution microscopy further revealed that the density of D4 domains, relative to the 
imaged cell area, increased after ketamine treatment in astrocytes (Fig. 5b), but not in PC12 cells and fibroblasts 
(Fig. 5c). In astrocytes (P < 0.001), the average density of D4-positive domains increased by 54% after treatment 
with 2.5 µM ketamine (0.57 ± 0.03 D4/µm2, n = 13) and by 41% after treatment with 25 µM ketamine (0.52 ± 0.03 
D4/µm2, n = 12), compared with controls (0.37 ± 0.03 D4/µm2, n = 12). The density of D4-positive domains 
in astrocytes (0.37 ± 0.03 D4/µm2, n = 12) was 62% to 73% higher (P < 0.001) than in PC12 cells (0.14 ± 0.01 
D4/µm2, n = 21) and fibroblasts (0.10 ± 0.01 D4/µm2, n = 27), respectively. Although the size of individual 
D4-positive domains differed (P < 0.001) in the cell types studied (PC12 cells, 0.080 ± 0.009 µm2; astrocytes, 
0.056 ± 0.001 µm2; fibroblasts, 0.037 ± 0.001 µm2), these appeared unaffected by ketamine (Fig. 5d). These results 
indicate that ketamine alters the membrane structure selectively in astrocytes.
Figure 3. cAMP treatment favors an open fusion pore state of vesicles transiently interacting with the 
plasmalemma. (a) An electrophysiological recording of the imaginary (Im) and real (Re) parts of the admittance 
signal measured in a cAMP-treated astrocyte where vesicles exhibited a longer transient fusion dwell time and 
a shorter transient fission dwell time. The baseline is denoted by a gray dotted line. The two vesicles undergoing 
transient fusion and fission are denoted by the numbers “1” and “2”, respectively. * denotes a calibration pulse. 
(b) The transient fusion dwell time of an open fusion pore is increased in cAMP-treated cells. (c) The transient 
fission dwell time of a closed fusion pore is decreased in cAMP-treated cells. Numbers in the bars denote the 
number of transient fusions (b) and fissions (c). *P < 0.05, ***P < 0.001 (Mann-Whitney U test).
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Discussion
Understanding the mechanisms of the antidepressant action of ketamine is crucial for improving therapeutic 
strategies for MDD, a worldwide burden1. The clinical effects of ketamine consist of a rapid (hours) and a sus-
tained (1–2 weeks) phases; the latter substantially outlasts the metabolic half-life of ketamine (~6 h)3. Although 
the rapid molecular pharmacology of ketamine activity is generally ascribed to NMDAR antagonism5, alternative 
pathways (such as ketamine modulation of cAMP-dependent cascades in the human brain) have been consid-
ered12. These pathways likely modulate brain function by primarily affecting the activity of astrocytes42.
Astrocytes are the primary homeostatic cells in the central nervous system that control homeostasis of major 
neurotransmitters, including glutamate, GABA, adenosine, and noradrenaline43. Major psychiatric disorders 
are associated with substantial decreases in astroglial density and in loss of astroglial functions, which argua-
bly results in an imbalance in neurotransmitter homeostasis and hence in aberrant information processing in 
neuronal networks44–50. At the molecular level, mood disorders are associated with astroglia-specific changes 
in serotonin receptors and intracellular signaling pathways51. Pharmacological approaches that could specifi-
cally target astrocytes in the context of neuropsychiatric disorders have not yet been developed. Nonetheless, we 
present results that indicate that ketamine exerts astroglial-specific effects, which can arguably be linked to its 
antidepressant potential.
Ketamine, a drug with multiple targets, affects several cellular signaling cascades, including exo- and endocy-
tosis18,52. Therefore, we first tested the hypothesis that ketamine regulates exo-/endocytosis through intracellular 
cAMP. We based this supposition on the recent finding that ketamine amplifies adrenergic receptor-mediated 
cAMP signaling in C6 glioma cells11. This in turn instigates the translocation of Gαs-proteins from lipid rafts, 
allowing them to interact with and activate adenylyl cyclase11. It is conceivable that Gαs-protein translocation 
could lead to an increase in [cAMP]i even in the absence of G-protein receptor stimulation. If ketamine-induced 
changes in the plasmalemmal structure are mirrored as lipid raft restructuring11, these may activate adenylyl 
cyclase and increase [cAMP]i. Indeed, we found that ketamine increased astroglial [cAMP]i (Fig. 1) in the absence 
of G-protein-activating neurotransmitters.
The ketamine-induced increase in [cAMP]i prompted us to compare the effects of both agents on vesicle 
fusion. It is generally accepted that cAMP potentiates exocytotic secretion22 by regulating fusion of vesicles with 
the plasmalemma through the cAMP sensor cAMP-GEFII (Epac2)53–55. Protein kinases can also regulate exo-
cytosis by increasing the population of vesicles sensitive to Ca2+ 56 with cAMP-dependent potentiation being 
associated with protein kinase A22. It was also proposed that fusion pore flickering depends on protein kinases57 
as well as cAMP19. As ketamine was reported to induce fusion pore flickering18, this led us to question whether 
these effects may be mediated via cAMP.
Figure 4. cAMP widens the vesicle fusion pore. (a,b) Electrophysiological recordings of the imaginary (Im) 
and real (Re) parts of the admittance signal. * denote calibration pulses. (a) An event in Im that is projected 
to Re in an untreated cell (left) and an unprojected event in a cAMP-treated cell (right). (b) A projected event 
with a smaller relative fusion pore conductance (Gp) (38 pS/1.4 fF = 27 pS/fF) in an untreated cell (left) and a 
projected event with a larger relative Gp (52 pS/0.7 fF = 74 pS/fF) in a cAMP-treated cell (right). The amplitudes 
of the events in Im and Re enable calculation of vesicle capacitance (Cv) and Gp (insert). (c) The proportion (%) 
of projected events. After cAMP treatment, a smaller proportion of events are projected to Re, indicating that a 
larger proportion of fusion pores are wider in cAMP-treated cells. (d) The relative Gp (pS/fF) is larger in cAMP-
treated cells. Numbers in the bars denote the number of cells (c) and projected events (d). **P < 0.01 (Mann-
Whitney U test).
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Our in-depth analysis of vesicle fusion in astrocytes reveals a clear difference between the effects of cAMP 
and ketamine. Whereas cAMP increases the probability of vesicular secretion (Figs 2–4, Supplementary Fig. 1), 
ketamine inhibits secretion of astroglial BDNF52. We found no effect of cAMP on the frequency of full vesicle 
Figure 5. Ketamine (KM) induces an increase in the density of cholesterol-rich domains in the plasmalemma 
of cultured rat astrocytes. (a) Confocal images of cultured astrocytes double-labelled with mCherry-D4 (D4, 
left) that stains cholesterol-rich domains in the extracellular leaflet of the plasma membrane, and with the non-
toxic B subunit toxin from Vibrio cholerae (CT-B, middle) conjugated to Alexa Fluor488, that interacts with the 
penta-saccharide chain of ganglioside monosialic acid (GM1), a constituent of sphingolipid- and cholesterol-
enriched lipid rafts. Mask image (right) displays substantial localization of GM1 in mCherry-D4-labelled lipid 
rafts in astrocytes. (b) SIM images displaying representative mCherry-D4-labelling in non-treated astrocytes 
(con) and astrocytes treated with ketamine (2.5 µM KM and 25 µM KM, respectively). Insets show mCherry-D4 
domains at a higher magnification. Scale bar (inset), 10 µm (1 µm). (c) The density of the membrane cholesterol 
domains (the number of cholesterol domains (D4) normalized to the cell surface area) significantly increased 
in astrocytes after treatment with 2.5 µM KM (0.57 ± 0.03 D4/µm2) and 25 µM ketamine (0.52 ± 0.03 D4/
µm2) compared with controls (0.37 ± 0.03 D4/µm2) (***P < 0.001, Holm-Sidak one-way ANOVA). Ketamine 
did not affect the density of the cholesterol-rich domains in the PC12 cell line and fibroblasts. The density of 
the D4-positive domains was significantly higher in astrocytes (0.37 ± 0.03 D4/µm2) compared with PC12 
cells (0.14 ± 0.01 D4/µm2) and fibroblasts (0.10 ± 0.01 D4/µm2) (***P < 0.001, Kruskal-Wallis test). (d) The 
average area of cholesterol-rich domains, measured in controls (treated with vehicle) and in cells treated with 
ketamine (2.5 µM and 25 µM) did not significantly differ in the PC12 cell line, fibroblasts and astrocytes, but it 
differed between different cell types. The average area of D4-positive domains was significantly higher in the 
PC12 cell line (0.080 ± 0.009 µm2) and astrocytes (0.056 ± 0.001 µm2) than in fibroblasts (0.037 ± 0.001 µm2) 
(***P < 0.001, Kruskal-Wallis test). The data in the graphs are reported as mean ± SEM. Numbers above the 
bars represent the number of cells analyzed.
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fusions; instead, cAMP facilitates widening of fusion pores and prolongs their open configuration (Figs 3 and 
4), as was previously described in pituitary cells19. The ratio between fusion pore conductance and vesicle size 
(Gp/Cv) represents a measure of exocytotic secretion58, and cAMP increases this ratio in astrocytes. An increase 
in astrocyte [cAMP]i promotes transient fusion of small synaptic-like vesicles (Fig. 2), as observed in pituitary 
cells19 in which Ca2+-dependent regulated exocytosis mediates the release of prolactin59. This suggests that cAMP 
preferentially stimulates full fusion of large non-synaptic-like vesicles60, whereas small vesicles remain attached 
to the plasmalemma with a narrow fusion pore (transient events). Consistent with this, immunocytochemical 
studies revealed that vesicles labelled with an antibody against VAMP2, a target of cAMP signaling and a marker 
of secretory vesicles21, are less abundant and of smaller diameter after cAMP treatment, indicating that cAMP 
prompts full fusion of larger secretory vesicles with the plasmalemma (Supplementary Fig. 1).
Our results also demonstrate that cAMP treatment results in the formation of larger early endosomes 
(Supplementary Fig. 2), suggesting homotypic vesicle-to-vesicle fusion between endosomal organelles, consistent 
with other studies that have suggested cAMP-evoked vesicle-to-vesicle fusion26. Homotypic fusion between ves-
icles also explains the amperometry results, which demonstrated that cAMP increased the quantal size of secre-
tory vesicles60–62. We have observed a similar effect with capacitance measurements in this study, which revealed 
more full fusions of larger vesicles in cAMP-treated astrocytes. Our results have now demonstrated that cAMP 
stimulates full fusion of larger (non-synaptic-like) vesicles, widens the fusion pore and prolongs the open fusion 
pore dwell time, thus increasing secretory activity. Therefore, the action of cAMP contrasts with the previously 
reported ketamine-mediated fusion pore stabilization in a narrow state, which inhibits vesicle cargo discharge18,52.
This study has demonstrated that, although ketamine increases [cAMP]i, ketamine and cAMP have a distinct 
effect on vesicle fusion. Hence, we tested an alternative hypothesis whether ketamine directly alters the structure 
of the plasmalemma.
We visualized the cholesterol-rich plasmalemmal domains with a fluorescent cholesterol-specific peptide D4 
from the toxin perfringolysin O40,41 that labels the outer leaflet of the plasmalemma. D4-positive punctate struc-
tures thus represent cholesterol-rich domains in the astrocyte plasmalemma (Fig. 5). The domain density, relative 
to the imaged cell area, increased significantly after ketamine treatment, yet the size of individual D4-positive 
domains remained the same (Fig. 5). Therefore, a relatively short exposure of cells to ketamine (30 min) results in 
a visible change in membrane structure. These changes are specific to astrocytes, because they were not observed 
in neural-like PC12 cells or in non-excitable fibroblasts (Fig. 5). Although it is unclear how ketamine specifically 
affects the density of cholesterol-rich domains in the plasmalemma (Fig. 6), the overall increase in cholesterol 
production is unlikely, since no increase in serum level of cholesterol was observed even after application of a 
high ketamine dose (120 and 140 mg/kg) to male Wistar rats that were sacrificed 20 min after the administration 
of ketamine63. Moreover, intraperitoneal administration of ketamine to male Wistar rats (1 mg/kg) for 6 days did 
not affect the cholesterol synthesis64. Supporting the notion that vesicle-based mechanism may be affected by 
ketamine through affecting the distribution of cholesterol in the plasma membrane, are experiments where the 
fusion of single vesicles with the plasmalemma was studied in the presence and absence of ketamine; the results 
revealed a robust stabilization of the fusion-pore in a narrow state, suggesting that endocytotic vesicles may not 
transfer from the transient fission to full fission state18. This may contribute to an increased density of cholesterol 
at the plasmalemma, since cholesterol-rich membrane domains may not be internalized via endocytosis. The 
availability of cholesterol appears to impair upon synapse development65, and our results suggest an important 
role of astrocytes in cholesterol homeostasis in the central nervous system. Astrocytes provide cholesterol to 
neurons, where it is needed for shaping neuronal structures which is particularly critical for synaptogenesis. The 
ketamine-induced increase in the density of cholesterol-rich domains in the astroglial plasmalemma may thus 
enable more intense flux of cholesterol molecules from astrocytes to neurons. We may therefore speculate that 
ketamine boosts plasticity in neural networks, although such a proposal requires further experimentation.
In conclusion, we here revealed that ketamine induces visible structural changes in the outer leaflet of the 
astroglial plasmalemma, observed as redistribution of cholesterol-rich domains. This action appears astroglia 
specific and may affect diverse homeostatic responses that could modulate the functional activity and plasticity 
Figure 6. A graphical representation of the ketamine-mediated increase in density of cholesterol-rich domains 
in the plasmalemma of cultured rat astrocytes. Note that the fluorescent construct mCherry-D4, a specific 
cholesterol marker, labels cholesterol-rich domains on the outer leaflet (OUT) of the plasmalemma.
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of neuronal networks. In particular, these changes may influence the flux of cholesterol from astrocytes to neu-
rons that is critical for morphological plasticity of synaptic connections65. In addition, structural changes of the 
astroglial plasmalemma likely affect adenylyl cyclase, with consequent increases in [cAMP]i in the absence of 
G-protein-coupled receptor stimulation11. This new mechanism of ketamine action may explain its multiple 
effects on depressive behavior and highlights the role of astrocytes in the search for new antidepressants.
Methods
Cell Culture and Transfection. Cell cultures of primary astrocytes were prepared and enriched from the 
neocortex of 2–3-day-old female Wistar rats as described52. The care for experimental animals was in accordance 
with the International Guiding Principles for Biomedical Research Involving Animals developed by the Council 
for International Organizations of Medical Sciences and the Animal Protection Act (Official Gazette RS, no. 
38/13). All experiments were performed in accordance with relevant guidelines and regulations. Specifically, 
we have followed the rules of Three R’s to reduce the impact of research on animals. The ex vivo experiments on 
Wistar rats were approved by the Veterinary Administration of the Republic of Slovenia (Apr. No. 3440-29/2006 
and 34401-29/2009/2).
PC12 cells (ATCC CRL-1721) and fibroblasts were grown at 37 °C, in 95% air/5% CO2 in growth medium 
containing high-glucose Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal bovine 
serum (FBS), 5% horse serum (Gibco, Gaithersburg, MD) and 25 µg/ml penicillin/streptomycin (PC12 cells) and 
α-MEM, supplemented with 10% FBS, 2 mM L-glutamine and 25 µg/ml penicillin/streptomycin (fibroblasts). 
When cells reached the 70–80% confluence, they were plated on coverslips and used within 3 days.
The acetoxymethyl ester of cAMP (cAMP-AM, A022, BIOLOG Life Science Institute) was applied to cells in 
serum-free medium. To optimize cAMP-AM loading, cells were pre-incubated for 15 min in DMEM without FBS; 
cAMP-AM (60 µM) or DMSO (0.2%; vehicle) were applied for 30 min.
Astrocytes were transfected with the genetically encoded fluorescence resonance energy transfer (FRET)-based 
cAMP nanosensor Epac1-camps28 as described66. Secretory vesicles were visualized by transfecting astrocytes 
with pANP.emd as described67. The culture medium was changed after 16 h; 48–72 h after transfection, cells were 
incubated in serum-free medium (15 min), and with 0.2% DMSO (vehicle) or 60 µM cAMP-AM (30 min), trans-
ferred to extracellular solution (ECS) with 0.2% DMSO or 60 µM cAMP-AM for microscopic observation. Unless 
otherwise noted, all chemicals were from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany).
Solutions. The extracellular bath and pipette solution consisted of (in mM): 131.8 NaCl, 5 KCl, 2 CaCl2, 1 
MgCl2, 10 d-glucose, and 10 HEPES/NaOH (pH 7.2). When intracellular cAMP was monitored, the bath solution 
consisted of (in mM) 1.8 CaCl2 and 2 MgCl2. Osmolality of the solution (300 ± 5 mOsm) was measured with a 
freezing-point osmometer (Osmomat030, Gonotech, Germany). cAMP-AM (60 µM) and DMSO (0.2%) were 
kept on ice and pipetted onto the coverslip (once a patch was established).
FRET Measurements of Cytosolic cAMP and Data Analysis. Astrocytes expressing the Epac1-camps28 
were examined 24–48 h after transfection with a Plan NeoFluoar 40×/1.3 NA oil differential interference contrast 
(DIC) immersion objective using a LSM510 META confocal microscope (Carl Zeiss, Jena, Germany). Real-time 
Epac1-camps FRET signal acquisition was performed as described66.
Unless stated otherwise, the FRET signal is reported as the ratio of the CFP/YFP fluorescence after subtracting 
the background fluorescence using Excel (Microsoft, Seattle, WA). The values of the FRET signals were normal-
ized to 1.0. An increase in the FRET signal reflects an increase in the [cAMP]i.
Initially, astrocytes were kept in ECS and treated with 25 µM ketamine (Tocris Bioscience, Bristol, UK) for 
900 s following a 100-s baseline. Control cells were treated with ECS (vehicle). The amplitude of the FRET signal 
(ΔFRET (%)) was determined for individual recordings by subtracting the mean FRET signal of the signal span-
ning the last 100 s before treatment from the first 100 s of the recording (baseline). The initial rate of the FRET 
signal change (ΔFRET/Δtime) was calculated for each recording as the slope of the linear regression function 
(ΔFRET (%) = slope (%/min) × Δtime (min)) fitting the initial FRET signal change.
Electrophysiology. Astrocyte-coated coverslips maintained in ECS were mounted on an inverted micro-
scope (Zeiss Axio Observer.A1). Compensated cell-attached patch-clamp recordings were performed to measure 
discrete step-like changes in membrane capacitance (Cm)68 and fusion pore conductance31. Full vesicle fusion/
fission was defined as a discrete upward/downward step in imaginary (Im) part of the admittance signal30 that 
was not followed by a step of similar amplitude (±15%) and opposite direction within 15 s, whereas transient 
vesicle fusion/fission was defined as a step in Im that was followed within 15 s, as reported previously18. As Cm is 
proportional to the membrane area, the vesicle surface area and diameter (d) were determined assuming spherical 
vesicle geometry and a specific membrane capacitance of 10 fF/μm2 31.
Immunocytochemistry. Immunocytochemical staining of astrocytes treated with 0.2% DMSO or 60 µM 
cAMP-AM (30 min) was performed as described52. The following primary antibodies were used: mouse mono-
clonal anti-EEA1 (1:100, 610456, BD Laboratories), mouse monoclonal anti-LC3 (1:100, M152-3, MBL), mouse 
monoclonal anti-VAMP2 (1:2000, 104211, Synaptic Systems), and rabbit polyclonal anti-VAMP3 (1:1000, ab5789, 
Abcam).
Dextran labelling. Astrocytes were incubated with 10 µM dextrans Alexa Fluor488 10,000 MW (D22910, 
Thermo Fisher Scientific) for 15 min or 3 h and subsequently in serum-free medium (15 min) containing 0.2% 
DMSO or 60 µM cAMP-AM (30 min), followed by washing in PBS and fixing with 2% formaldehyde (10 min). 
After washing in PBS, coverslips were mounted onto glass slides using Slow Fade Gold Antifade agent (Thermo 
Fisher Scientific).
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mCherry-D4-PFO and EGFP-D4-PFO expression and purification. For the construction of a plasmid 
encoding a His-Tag-eGFP-D4 or His-Tag-mCherry-D4 fusion proteins, a DNA fragment containing eGFP or 
mCherry coding region was first cloned into the pGA2.1 bacterial expression vector69 after removing Equinatoxin 
II coding sequence using XhoI and MluI sites. Flexible Gly-Ser linker and additional AvrII restriction site were 
created at 3′ end of the gene encoding fluorescent protein as non-complementary ends of the amplification prim-
ers. In the next step, DNA fragment encoding for D4 domain of PFO was introduced into the prepared vector 
using AvrII and MluI restriction sites. The tagged D4-PFO variants were expressed in E. coli BL21(DE3) cells, 
which were grown in 1 l of LB medium supplemented with 100 µg/ml ampicillin (LBA) to an A600 of 0.5–0.7, 
induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubated overnight at 20 °C, with 
shaking at 180 rmp. The bacteria were harvested by centrifugation for 15 min at 4 000 g and 4 °C, resuspended in 
10 ml/g wet mass of lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) and lysed by sonica-
tion. Cellular remnants were removed by centrifugation at 50 000 g for 1 hour at 4 °C. The supernatant was filtered 
through a 0.2-µm cellulose-acetate filter, added to the 0.5 ml 50% Ni-NTA slurry (Ni-NTA Superflow, Qiagen) 
and incubated at 4 °C on a rotary shaker for 60 minutes. Lysate-Ni-NTA mixture was loaded on polypropylene 
columns, washed twice with 10 ml wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0) 
and the protein was eluted with 2 ml of elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 
8.0). Purified protein was dialyzed (Slide-a-lyzer from Thermo Scientific, 10 000 MWCO) against 0.5 l of a buffer 
(50 mM Tris-HCl, 200 mM NaCl, 5% (v/v) glycerol, pH 7.4).
Cholesterol and Ganglioside Monosialic Acid (GM1) Staining. Astrocytes, PC12 cells and fibroblasts 
were exposed to 2.5 or 25 µM ketamine for 30 min at 37 °C in culture medium; controls were exposed only to ECS. 
Cells were washed with ECS at room temperature (RT) and mCherry-D4 (0.25 µM) was applied for 30 min at RT. 
Then cells were washed with ECS 3× for 3 min at RT, fixed in 4% formaldehyde for 10 min at RT, and washed with 
ECS 3× for 3 min at RT. Samples were mounted onto glass slides with Slow Fade Gold Antifade agent. In a subset 
of experiments, astrocytes were first labelled by mCherry-D4 (0.25 µM) and then by the non-toxic B-subunit 
toxin from Vibrio cholerae (CT-B) conjugated to Alexa Fluor488 (Thermo Fisher Scientific) that interacts with the 
penta-saccharide chain of ganglioside monosialic acid (GM1), as described70.
Structured Illumination Microscopy and Image Analysis. Astrocytes labelled with dextrans, antibod-
ies or mCherry-D4 were imaged with a Zeiss ELYRA PS.1 super-resolution microscope with an oil-immersion 
plan apochromatic DIC objective (63×/NA 1.4), an EMCCD camera (andor iXon 885, Andor Technology, 
Belfast, UK), and 5 different grating directions for SIM.
Alexa Fluor488 and Alexa Fluor546/mCherry-D4 were excited by 488 nm argon and 561 nm DPSS laser lines, 
respectively, and emission fluorescence was filtered with 495–575 nm or 570–650 nm bandpass filters. The num-
ber and surface area of fluorescent vesicles were obtained by exporting tiff images to ImageJ (NIH, Bethesda, 
MD). To identify individual vesicles, the intensity threshold was set to 20% of the maximum fluorescence, and 
the minimum fluorescent spot size considered to be a vesicle was five adjacent pixels (5 × 0.04 × 0.04 µm); the 
minimum surface area covered by a vesicle was 0.008 µm2.
In mCherry-D4-stained cells, we acquired 500-nm thick z-stacked images that were analyzed in Fiji71. 
Individual cells were cropped and auto-thresholded with IsoData method to measure number and the area of 
D4-labelled entities in the range of 7–3000 pixels (0.01–4.80 µm2).
Confocal Microscopy and Image Analysis. Z-stacked confocal images of astrocytes expressing ANP.emd 
were obtained with a Zeiss LSM 780 as described17. The number and surface area of ANP.emd-positive vesicles 
were obtained by ImageJ. The intensity threshold was set to 20% of the maximum fluorescence and the minimum 
spot size considered to be an individual vesicle was four pixels (4 × 0.088 × 0.088 μm); the minimum surface area 
covered by a vesicle was 0.031 µm2. Double-fluorescent (mCherry-D4- and CT-B-labelled) cells were observed by 
a plan-apochromatic oil-immersion objective 63×/NA 1.4. Z-stacked images were obtained with a 488-nm argon 
laser and 561-nm diode-pumped solid-state laser excitation; the emission fluorescence was bandpass filtered at 
500–550 nm and 590–640 nm, respectively. Fluorescence co-localization between green-emitting Alexa Fluor488 
and red-emitting mCherry-D4 was quantified in 8-bit TIFF files exported to ColocAna software72 as described70.
Statistics. Data analysis was performed with SigmaPlot (Systat Software, San Jose, CA). The parameters are 
presented as mean ± SE. Unless stated otherwise, Student’s t test and the Mann-Whitney U test were used to 
determine statistical significance; P < 0.05 was considered significant.
Data Availability
All data generated or analyzed during this study are included in this published article and its Supplementary 
Information files or are available from the corresponding author on reasonable request.
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